GT Biopharma, Inc. (GTBP) Earnings
GT Biopharma, Inc.'s most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Last reported earnings
Nov 14, 2025
From the latest earnings 8-K
Revenue • FY2025
$0
As reported
Diluted EPS • FY2025
-$6.68
▲ 3.7%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from GTBP's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $0 | -$28.35M | — | -$6.68 | — | — | — |
| FY2024 | $0 | -$13.16M | — | -$6.94 | — | — | — |
| FY2023 | $0 | -$7.6M | — | -$5.64 | — | — | — |
| FY2022 | $0 | -$20.88M | — | — | — | — | — |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Nov 14, 2025 | 8-K (2.02) | 0001493152-25-022631EDGAR |
Never miss a GTBP filing.
Get an email when GTBP files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Nov 9, 2026Source: SEC EDGAR.